BFM
ADPT icon

Boothbay Fund Management’s Adaptive Biotechnologies ADPT Stock Holding History

Boothbay Fund Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,705
Closed -$343K – 2209
2026
Q1 		$343K Buy
+24,705
New +$394K ﹤0.01% 1552
2025
Q4 		– Sell
-64,369
Closed -$963K – 1917
2025
Q3 		$963K Buy
+64,369
New +$784K 0.01% 851
2020
Q2 		– Sell
-7,400
Closed -$206K – 942
2020
Q1 		$206K Sell
7,400
-1,600
-18% -$44.6K 0.02% 659
2019
Q4 		$269K Buy
+9,000
New +$258K 0.02% 622

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Boothbay Fund Management's ADPT Position: Q2 2026 in Review

Boothbay Fund Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 24,705 shares — an estimated $343K sold.

Boothbay Fund Management first reported a position in ADPT in Q4 2019 and held it in 4 quarters. The position peaked at $963K in Q3 2025. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Boothbay Fund Management reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 24,705 Adaptive Biotechnologies shares in Q2 2026, an estimated $343K.
  • Boothbay Fund Management first reported a position in Adaptive Biotechnologies in Q4 2019 and held it in 4 quarters.
  • Boothbay Fund Management's Adaptive Biotechnologies position peaked at $963K in Q3 2025.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.